Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FDA hearing on CBD started today.
Why the sudden drop in share price? Thought I'd missed out when I didn't buy in back at the first of the year when they were advertising on Time Square for New Year's Eve.
imho $ELLXF GOING MUCH HIGHER
excerpt-***Regardless of whether or not the FDA offers greater clarity after this Friday's public hearing, demand for CBD is exploding ... and doesn't appear to be slowing
Last year, retail sales of CBD products in the U.S. were estimated between $600 million and $2 billion, according to the investment research firm Cowen. By 2025, the group conservatively forecasts sales to reach $16 billion, with health and wellness products leading the way.
It's growth like this that's leading to massive investment gains from CBD-related stocks. For example, take Elixinol Global Limited.
Down on the asx
thinking any dips to around $3.40 are a great point to increase position
Wondering if this started the ASX pps decline.
5/22: https://stockhead.com.au/news/ig-markets-stops-all-trading-in-pot-stocks-tells-investors-to-sell-by-may-24/?utm_medium=email&utm_campaign=Lunchtime%20ASX%20small%20cap%20wrap%20Thur%20May%2023&utm_content=Lunchtime%20ASX%20small%20cap%20wrap%20Thur%20May%2023+CID_f06c038db444b37ab075f64bc28ce874&utm_source=Campaign%20Monitor&utm_term=IG%20Markets%20stops%20all%20trading%20in%20pot%20stocks%20tells%20investors%20to%20sell%20by%20May%2024
I STILL LIKE, STEADY $ELLXF
Check out Page 13 of CEO Presentation.
And Page 14.
https://www.elixinolglobal.com/site/PDF/2474_0/2019AGMCEOPresentation?fbclid=IwAR1y_CjMR8StODJszzUe_jiW1TrFqDDbyANb_Hu1bFsJWiDMTKtrYn30YwQ
From Barrons: Link should open. They state of the 4 stocks to ride wave; Elixinol is one of them. In company with Charlottes web and CVSI.
https://www.barrons.com/articles/4-stocks-to-ride-the-cbd-wave-51558448900?mod=hp_LATEST
https://finance.yahoo.com/news/medipharm-labs-australia-awarded-cannabis-205000465.html
I see this as more good news for ELLXF.
Not a matter of legality or legislation just a matter of time
Thanks for sharing.
Elixinol has probably the most SKUs developed within pure CBD companies since they have skin line and recently they bought stake in pet CBD company
From Austalia's Hot Copper message board...
https://hotcopper.com.au/threads/exl-in-safeway-stores-in-u-s.4763594/
ELLXF:"US supermarket chain Safeway is carrying Elixinol products in its 900 stores — a fact that hasn’t yet been announced by Elixinol but was noted and photographed by a sharp-eyed friend of an ASX investor."
https://stockhead.com.au/health/a-third-of-us-cbd-companies-are-about-to-disappear-and-thats-great-news/
It was the election in Aus....Conservative won...He wasn't expected to win.. Its down on the asx...I guess we will find out next week how this goes...
Australian ASX opens local at 730pmEST - nice to get a feel for the potential direction of this play everyday.
No not that i see...The MJ index is gaining steam with good numbers out...I expect some big news after may 31st when the fda gives some guidance on Hemp Cbd....With the recent tariffs added on farmers something has to give...June could be a bullish month for Hemp related companies.....
Strong day out of nowhere. Lots of buying coming in whole day. Do we have some news that we don't see ?
Trending upward again
Looking like it will Gap Up this morning.
ELLXF: Elixinol Partners with Cambrian Alliance
Elixinol and Cambrian Alliance Partner to Offer Unparalleled Access to the Highest Quality CBD to Cambrian Alliance Members
DENVER, May 14, 2019 (GLOBE NEWSWIRE) -- Elixinol, one of the most influential CBD brands in the world with nearly three decades of experience in the hemp industry, today announced that they have partnered with Cambrian Alliance (CA), one of the largest buying groups for independent pharmacies in the United Kingdom. The partnership allows CA members to access Elixinol brand products, an exclusive launch offer package, point of sale material and staff training.
“We are delighted to work in partnership with Elixinol, providing our members with access to a new range of products,” said Nathan Wiltshire, CEO of Cambrian Alliance. “Our active goal is to help our members grow their businesses and increase their profits, and this new partnership strengthens our commitment to ensuring this ambition.”
Elixinol is in the process of developing an interactive training platform for CA members in support of the partnership. This platform will help members explain the various benefits of Elixinol products to their customers and maximize CBD revenue opportunities. The deal will be offered across Cambrian’s 1,200 member stores, with each store independently deciding on offer integration.
“As one of the most trusted industry leaders, Elixinol is delighted to work with Cambrian Alliance as the organization and its membership share our core values and commitment to excellence,” said Ali Atcha, Sales & Marketing Director at Elixinol Europe. “We will be offering unrivaled retail support to member pharmacies looking to grow their business with our high quality, trusted CBD products.”
Gravells Pharmacy, a Cambrian Alliance member store in South Wales, is already experiencing the benefits of retailing Elixinol CBD products. James Thorne from Gravells commented, “I’ve tried around ten different CBD brands with my customers and nothing I’ve found in the marketplace can touch Elixinol for quality and effectiveness. Our sales are growing fast.”
About Elixinol:
Colorado-based Elixinol, co-founded by Paul Benhaim, hemp entrepreneur since 1991, is widely regarded as one of the most influential CBD brands in the world. With a proven track record of growing and extracting premium-quality hemp, Elixinol is one of the few CBD hemp extract brands with complete seed-to-sale control over its products. Elixinol also conducts rigorous third-party laboratory testing and quality control. Elixinol distributes hemp-derived CBD products in 40 countries globally including North and South America, throughout Europe, Asia, and the Pacific Region under its own label as well as bulk CBD and wholesale CBD. Elixinol’s parent company EXL (elixinolglobal.com) is publicly traded on the Australian Securities Exchange and on the U.S. OTC (ASX:EXL, OTCQX: ELLXF). More information available at Elixinol.com.
About Cambrian Alliance:
The Cambrian Alliance Group is one of the UK’s largest pharmacy buying groups with over 1,200 members, working with leading suppliers including AAH and Alliance Healthcare. It was launched in 2000 by six community pharmacists who continue to direct the company. With core values of integrity, honesty, personalization and transparency, the organization boasts 10 regional Business Managers covering the whole of the UK to advise and support its members, as well as a dedicated PMR-based price comparison, stock ordering tool e-CASS is used by over 600 pharmacies.
Media Contact:
Blythe Tokar
MULTIPLY
202-292-4573
multiply@elixinol.com
Chris Husong
Elixinol
+1 844-804-3504 ext 420
chris@elixinol.com
ELLXF Granted CBD processor licence and research
authorization by New York State:
insert-text-here
Updated Investor Presentation: insert-text-here
May 10, 2019 04:53 PM ET (BZ Newswire) -- Cannabis
Although the legal marijuana industry is still very much an emerging niche for stock market participants, the market for investing in cannabis is maturing.
In a recent sign of how far the legal cannabis sector has come, BlackRock Funds has made substantial investments in dispensary operator Curaleaf Holdings, the same company that also announced it will sell products infused with a non-psychoactive hemp component in CVS Health Corp (NYSE:CVS) stores.
Institutional Investment, Industrialized Processes
The CVS deal indicates that cannabis products are becoming more mainstream. The BlackRock investment is a high-profile example of institutional money entering a space that has been called the Wild West of investing. “We expect to see a floodgate [open] of more institutional investment,” said Matt Karnes, founder and managing partner with GreenWave Advisors.
More institutional money would help increase the liquidity of the sector—a good thing for investors who don’t want to get stuck holding an investment they may wish to sell. And if institutional money is now considering the space, it stands to reason that more retail-level investors might be wondering how to invest in cannabis, especially as the industry matures.
“We’re seeing more credibility in terms of management stepping into the industry,” Karnes explained, adding that executives have been migrating to the sector from the pharmaceutical and consumer packaged goods industries.
And with the push for legalization, marijuana companies are becoming more industrialized. Previously, the illegal industry was served by growing operations that weren’t very scalable, including those inside houses, according to Alan Brochstein, partner with New Cannabis Ventures and an analyst and portfolio manager with 420 Investor. Now, companies are using bigger facilities with heating, air conditioning, greenhouse, and larger-scale lighting technologies, he said.
Canadian and U.S. Cannabis Stocks
Marijuana companies can be broadly divided into those that grow, process, sell, or distribute cannabis directly and those that service the industry, including with packaging and hydroponic supplies. There’s also the biotech segment of the industry, which aims to get products licensed through the government.
Choices Growing?
Although the classic image of marijuana use may be someone smoking a joint or eating a pot-infused brownie, as the cannabis industry matures, new ways of using both the psychoactive component THC as well as CBD (which won’t get you high) are blooming.
Beauty industry and health-and-wellness products abound, including CBD-infused lotion and lip balm.
There’s also CBD-infused coffee, which proponents say can increase focus.
For those interested in the psychoactive effects of THC but don’t want to smoke or pack on the pounds with brownies, there are several THC oral sprays on the market.
Also for those who don’t want to smoke, there are beverages with THC in them, such as an infused (alcohol-free) margarita.
For those interested in smoke-free relaxation, there are several bath soaks with THC extract.
Consumer segmentation is occurring, as some companies are targeting certain users with products containing lower doses of THC than other products.
Another important division for those considering investing in the cannabis industry is Canadian versus American cannabis stocks. In Canada, pot is recreationally and medically legal at the federal level, whereas it remains a controlled substance federally in the United States even though a patchwork of states have legalized it in some capacity.
The regulatory risk is lower in Canada because pot companies don’t have to worry about the federal government seizing their assets and their executives going to jail, according to Brochstein. He added that although regulatory risk is higher for U.S. companies, they look better from a valuation and potential growth standpoint.
Ways to Invest in the Cannabis Industry
Investors wanting to get in early with a new cannabis company can consider investing in an initial public offering (IPO). When it comes to investing in IPOs, investors should be cautious. And with the special rules specific to this industry, cannabis IPOs could be considered even more risky investments than usual.
Plus, the cannabis IPO market—which often involves companies going public through reverse mergers—is very speculative, Karnes cautioned. “Not all of these reverse mergers have been successful out of the gate,” he said.
Plus, at this point, the cannabis IPO market seems to be getting flooded with new entries, making it less appealing.
Of course, investors can buy individual stocks, but that means doing homework on their markets, management, and finances. Another way to invest in cannabis stocks without buying company shares individually is to use exchange-traded funds (ETFs). Although ETFs can offer a way to distribute your investment across a range of companies, they won’t reduce the risks in the broader market, nor those inherent to the cannabis industry.
Investing in Cannabis Stocks Is Risky
JJ Kinahan, chief market strategist at TD Ameritrade, noted that investing is difficult enough without adding the legislative burden that hangs over U.S. cannabis stocks.
For those who do want to take the plunge, cannabis companies should be a small part of their portfolio, and investors need to have a certain level of comfort holding risky investments for a long period of time, according to Kinahan. “Are you willing to sit with something knowing that there’s going to be a lot of emotional and perhaps legal upheaval?” he asked.
Brochstein advised investors should consider the management teams of marijuana companies. If you can’t find out much about the people running the company, that’s a red flag.
Another tip Brochstein has for potential investors in the marijuana space is to understand the capital raising cycle. When companies announce capital raises, their stock can get hammered, which he suggested could be a good time to buy depending on your investment style and risk tolerance.
Brochstein also recommended that investors should read a company’s actual filings, as press releases often contain a positive spin even on bad news.
“Do your homework,” Karnes said, quipping: “There are a lot of snakes in the grass.”
Information from TDA is not intended to be investment advice or construed as a recommendation or endorsement of any particular investment or investment strategy, and is for illustrative purposes only. Be sure to understand all risks involved with each strategy, including commission costs, before attempting to place any trade.
Image sourced from Pixabay
Copyright © 2019 Benzinga (BZ Newswire, http://www.benzinga.com/licensing). Benzinga does not provide investmentadvice. All rights reserved. Write to editorial@benzinga.com with any questions about this content. Subscribe to Benzinga Pro (http://pro.benzinga.com).
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Elixinol mentioned as a big name in Colorado: https://investorplace.com/2019/05/6-signs-that-marijuana-legalization-is-closer-than-you-think/?mod=mw_quote_news
Appears to be a pattern forming of being able to buy under $3.20 and make 5-10% on a day trade play?
Understaffing costs manufacturing, jobs: Cannabis CEO
http://www.foodanddrinkbusiness.com.au/news/understaffing-costs-manufacturing-jobs-cannabis-ceo?fbclid=IwAR2TRWgd_cBBXhbE32XzIAsxwLjsNGMqewoU5OjyNvknu7o97X3VqvvSI5U
Profitability and margins are a key for me.
CWBHF and ELLXF got it.
KSHB not even close.
I have not bought into KUSH yet, but I am a firm believer that those that sold picks and shovels during the 'gold rush' made more that those they sold them to.
Also watching Item 9...
So far just bought into CWEB and ELLXF. Being cautious on trying to get best of breed that I can hold for years to come.
Yes, as I said it is paid service by investors. Investors Cannabis do DD and share with whoever is subscribed. Newsletters or alerts are not paid by the companies themselves.
They review cannabis stocks and create profolio including just a few picks. I don't think there is more than 10 that they gave recommendations to buy.
They recommended to buy half position of in January and then second half in February.
There was no recommendation to sell anything yet.
That to be said, I don't agree with some of their picks like Kush Bottles.
Ahhh ok...Thanks....Cant wait for the name of the grocery store
Guess the next post answered my question... Thanks
So it's not a paid pump. Just a chart room/ news letter alert?
Alert brought good update and solid DD on a company. ALLXF is still under radar so bringing more eyes and creating volume is good. Imo
It's not some type of alery that penny stocks do to pump stock to dump shares so it is all good imo
Yes, I'm signed up to Cannabis Investor's and get alerts from them. I believe today was 3rd one on ELLXF.
Previous two were strong buy recommendations (on 01/22 and 02/14)
Today looks like update on company.
Ehhh alerts. ....I rather have some news...O well lol
Yes, this is the third since I've been following ELLXF. No idea who Cannabis Investor's Report is, but both others came around 1 in the afternoon and created record volume that spilled over to the next day. We didn't see any text for the last 2, just that an alert had gone out.
Two previous ones? Not sure what the other two were.. lol. Who is alerting this? Just curious
ANIA77 told us about the Alert on 1/22.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146262815
I think the other one came mid-February where the chart shows two days of record volume.
It was an Alert from same source as two previous ones. Both others produced very high volume with pps increase of 7-9% during the day and a close of 2-3% up.
Yes i read it after i posted...The FDA is also coming to a consensus on cbd for pets this month...
Someone posted something below... looked interesting but I think was a newsletter. Either way good action off low
Yea trying to figure out whats going on here...
Followers
|
26
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1174
|
Created
|
09/18/18
|
Type
|
Free
|
Moderators |
50 Pitt Street,
Level 6
Sydney, NSW 2000
Australia
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |